Tocilizumab is useful for coronavirus disease 2019 patients: the key point is timing

Autor: Muhammet Gülhan, Uğur Önal, Neşe Demirci, Gulcan Cetin, Abdullah Calisir, Damla Köksalan, Kübra Solmaz, Ayhan Kars, Cetin Kilinc, Sedat Gülten

Publikováno v: Revista da Associação Médica Brasileira v.68 n.3 2022
Revista da Associação Médica Brasileira
Associação Médica Brasileira (AMB)
instacron:AMB
Revista da Associação Médica Brasileira, Volume: 68, Issue: 3, Pages: 318-322, Published: 15 APR 2022

SUMMARY OBJECTIVE: In coronavirus disease 2019, a rapidly progressive inflammatory process is considered to be the main cause of organ damage and mortality. Therefore, the importance of anti-inflammatory treatments such as tocilizumab is increasing.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbd72931d5c3d925df31a772c950e571
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302022000300318